Mannie, Mark D.Curtis II, Alan Dale2020-04-022020-04-022013-01-28http://hdl.handle.net/10342/7818Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.autoimmune disease, experimental autoimmune encephalomyelitis, immune, multiple sclerosis, myelin, neuroantigen, T lymphocytes, therapy, tolerance, vaccineArticle10.4161/hv.23685